Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Drugs Dermatol. 2009 May;8(5):467-74.

Beyond a decade of 5% imiquimod topical therapy.

Author information

  • 1Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. agasp001@umaryland.edu


The therapeutic potential of imiquimod, a toll-like receptor (TLR)-7 agonist, was recognized in the clinical setting more than a decade ago. Beginning with an approved indication for the treatment of external genital warts in 1997, imiquimod 5% topical cream (Aldara) has received further approval for treating actinic keratosis and superficial basal cell carcinoma. Currently, imiquimod 5% topical cream is the most widely studied and characterized TLR agonist available in the clinical milieu. With new formulations and adjunctive regimens being studied, this paper briefly reviews the mechanisms of action, approved indications, exploratory indications and the role of combination therapy, add-on molecules, and new formulations to overcome treatment limitations.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk